The forecasted sales of cardiac glycosides in Germany from 2024 to 2028 show a continuous year-on-year decline in value:
- 2024: €15.3M
- 2025: €14.5M (-5.23%)
- 2026: €13.8M (-4.83%)
- 2027: €13.1M (-5.07%)
- 2028: €12.5M (-4.58%)
The average Compound Annual Growth Rate (CAGR) from 2024 to 2028 stands at -5.02%, indicating a consistent downward trend.
Future Trends to Watch: Factors influencing this decline could include advancements in alternative treatments, changes in clinical guidelines, or shifts in healthcare policies. Monitoring these elements is crucial for understanding the long-term market trajectory.
